January 26, 2026 — Leads & Copy — Arcus Biosciences, Inc. (NYSE:RCUS) announced today that the Compensation Committee of its Board of Directors has granted three new employees options to purchase 16,650 shares of the Company’s common stock. The exercise price is set at $22.13 per share, the closing price on January 23, 2026. Additionally, restricted stock units were granted to acquire 8,400 shares of the Company’s common stock.
The equity awards were granted under the Company’s 2020 Inducement Plan. This plan was approved by the Board of Directors in January 2020, in accordance with the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences, founded in 2015, is focused on creating differentiated molecules for cancer, inflammatory and autoimmune diseases. The company has multiple investigational medicines in registrational clinical trials, including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer.
Arcus Biosciences is a global biopharmaceutical company dedicated to developing differentiated molecules and combination therapies for individuals affected by cancer, inflammatory, and autoimmune conditions. Working with industry collaborators, patients, and physicians, Arcus aims to accelerate the development of its portfolio of medicines against biological targets and pathways. The company is also studying novel, biology-driven combinations with the potential to extend the lives of people with cancer.
For further details on Arcus Biosciences’ clinical and preclinical programs, visit www.arcusbio.com.
Source: Arcus Biosciences
